ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.510,82
-0,48%
S&P 500
5.631,22
0,00%
Dow Jones
40.211,72
0,00%
Euro vs US Dollar
1,08919
-0,07%
Bitcoin
64.016,53
-1,29%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Avid Bioservices Inc (CDMOP)

  7. Avid Bioservices Inc (CDMOP) News

CDMOP

Avid Bioservices (CDMOP)

Avid Bioservices Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CDMOP
DatumZeitQuelleÜberschriftSymbolFirma
22/06/202122h05GlobeNewswire Inc.Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, ...NASDAQ:CDMOPAvid Bioservices Inc
25/05/202114h05GlobeNewswire Inc.Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)NASDAQ:CDMOPAvid Bioservices Inc
08/05/202101h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CDMOPAvid Bioservices Inc
15/04/202122h05GlobeNewswire Inc.Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred StockNASDAQ:CDMOPAvid Bioservices Inc
12/04/202122h39Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:CDMOPAvid Bioservices Inc
19/03/202122h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CDMOPAvid Bioservices Inc
17/03/202113h05GlobeNewswire Inc.Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor ForumNASDAQ:CDMOPAvid Bioservices Inc
10/03/202106h20GlobeNewswire Inc.Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior NotesNASDAQ:CDMOPAvid Bioservices Inc
08/03/202123h01GlobeNewswire Inc.Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior NotesNASDAQ:CDMOPAvid Bioservices Inc
08/03/202122h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CDMOPAvid Bioservices Inc
08/03/202122h05GlobeNewswire Inc.Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent DevelopmentsNASDAQ:CDMOPAvid Bioservices Inc
03/03/202122h46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CDMOPAvid Bioservices Inc
03/03/202122h05GlobeNewswire Inc.Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockNASDAQ:CDMOPAvid Bioservices Inc
01/03/202122h05GlobeNewswire Inc.Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021NASDAQ:CDMOPAvid Bioservices Inc
22/02/202123h11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CDMOPAvid Bioservices Inc
22/02/202114h05GlobeNewswire Inc.Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion PlanNASDAQ:CDMOPAvid Bioservices Inc
16/02/202121h32Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CDMOPAvid Bioservices Inc
12/02/202114h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CDMOPAvid Bioservices Inc
03/02/202113h00GlobeNewswire Inc.Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Suppo...NASDAQ:CDMOPAvid Bioservices Inc
03/02/202113h00Business WireHumanigen & Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support...NASDAQ:CDMOPAvid Bioservices Inc
29/01/202112h04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CDMOPAvid Bioservices Inc
26/01/202122h19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CDMOPAvid Bioservices Inc
19/01/202122h40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CDMOPAvid Bioservices Inc
05/01/202100h22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CDMOPAvid Bioservices Inc
14/12/202022h43Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CDMOPAvid Bioservices Inc
14/12/202022h05GlobeNewswire Inc.Avid Bioservices Announces Closing of Public Offering of Common StockNASDAQ:CDMOPAvid Bioservices Inc
11/12/202023h16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CDMOPAvid Bioservices Inc
10/12/202015h00GlobeNewswire Inc.Avid Bioservices Announces Pricing of Public Offering of Common StockNASDAQ:CDMOPAvid Bioservices Inc
09/12/202022h53Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CDMOPAvid Bioservices Inc
09/12/202022h45GlobeNewswire Inc.Avid Bioservices Announces Proposed Public Offering of Common StockNASDAQ:CDMOPAvid Bioservices Inc
 Showing the most relevant articles for your search:NASDAQ:CDMOP

Kürzlich von Ihnen besucht

AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
COIN
SOLUSD
Solana
CCOM
US500
US 500
NASDAQ
AMZN
Amazon.com
CCOM
SILVER
SILVER
TG
NOV
Novo Nordisk
NYSE
DIS
Walt Disney
DBI
DAX
DAX
NYSE
JPM
JP Morgan Chase
TG
RHM
Rheinmetall
USOTC
BASFY
BASF (QX)
CCOM
US100
US Tech 100
CCOM
US30
US 30
TG
432
Arbor Metals
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten